Trial · NCT01877564
A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
NCT01877564, Phase 2, Completed, University of Arkansas; results first posted 2017-10-25
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women. Trials, record NCT01877564. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01877564
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women
- NCT number
- NCT01877564
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 10 participants, actual
- Lead sponsor
- University of Arkansas
- Conditions
- Adenocarcinoma of the Endometrium
- Interventions
- Metformin
- First posted
- 2013-06-13
- Last updated
- 2017-10-25
- Results first posted
- 2017-10-25
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | IHC-based Tissue Markers of Proliferation | 1 year |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | IHC-based Tissue Markers of Proliferation | 1 year | data were not collected |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Group 1 - Metformin | 6 | |
| Overall Study | STARTED | Group 2 - No Treatment | 4 | |
| Overall Study | COMPLETED | Group 1 - Metformin | 6 | |
| Overall Study | COMPLETED | Group 2 - No Treatment | 4 | |
| Overall Study | NOT COMPLETED | Group 1 - Metformin | 0 | |
| Overall Study | NOT COMPLETED | Group 2 - No Treatment | 0 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | dysuria | Renal and urinary disorders | Group 1 - Metformin | 1 | 6 | 1 |
| other | dysuria | Renal and urinary disorders | Group 2 - No Treatment | 0 | 4 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Group 1 - Metformin | 0 | 6 |
| Total, all-cause mortality | Group 2 - No Treatment | 0 | 4 |
| Total, other adverse events | Group 1 - Metformin | 1 | 6 |
| Total, other adverse events | Group 2 - No Treatment | 0 | 4 |
| Total, serious adverse events | Group 1 - Metformin | 0 | 6 |
| Total, serious adverse events | Group 2 - No Treatment | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Group 1 - Metformin vs Group 2 - No Treatment: deaths from any cause | Trial comparisons |
| Group 1 - Metformin vs Group 2 - No Treatment: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01877564
GET https://conductscience.org/api/trials/v1/NCT01877564/registered